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Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes which catalyze the hydration
of carbon dioxide to bicarbonate and protons. Many pathogenic bacteria encode such
enzymes belonging to the α-, β-, and/or γ-CA families. In the last decade, the α-CAs from
Neisseria spp. and Helicobacter pylori as well as the β-class enzymes from Escherichia coli,
H. pylori, Mycobacterium tuberculosis, Brucella spp., Streptococcus pneumoniae, Salmo-
nella enterica, and Haemophilus inﬂuenzae have been cloned and characterized in detail.
For some of these enzymes the X-ray crystal structures were determined, and in vitro and
in vivo inhibition studies with various classes of inhibitors, such as anions, sulfonamides
and sulfamates reported. Although efﬁcient inhibitors have been reported for many such
enzymes, only for Neisseria spp., H. pylori, B. suis, and S. pneumoniae enzymes it has
been possible to evidence inhibition of bacterial growth in vivo. Thus, bacterial CAs rep-
resent promising targets for obtaining antibacterials devoid of the resistance problems of
the clinically used such agents but further studies are needed to validate these and other
less investigated enzymes as novel drug targets.
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INTRODUCTION
Resistance to antibiotics belonging to several different classes is
escalating and represents a worldwide problem (Ginsberg, 2008;
Dye, 2009; Furtado and Nicolau, 2010), as both Gram-negative
and Gram-positive bacteria (such as among others Staphylococ-
cus aureus, Mycobacterium tuberculosis, Helicobacter pylori, Bru-
cella suis, Streptococcus pneumoniae, etc.,) no longer respond
to many such drugs (Cloeckaert and Schwarz, 2001; Nickerson
and Schurr, 2006; Bush and Macielag, 2010). Cloning of the
genomes of many bacterial pathogens offers however the pos-
sibility to explore alternative pathways for inhibiting virulence
factors or proteins essential for their life cycle (Suerbaum and
Michetti, 2002; Payne et al., 2007; Showalter and Denny, 2008;
Tsolis et al., 2008). Among the many such new possible drug
targets explored recently, are a class of enzymes catalyzing a sim-
ple but physiologically relevant process, carbon dioxide hydration
to bicarbonate and protons (Smith et al., 1999; Supuran, 2008,
2010a,b). These enzymes are denominated carbonic anhydrases
(CAs, EC 4.2.1.1), and they are all metalloenzymes. Five differ-
ent genetically distinct CA families are known to date, the α-,
β-, γ-, δ-, and ζ-CAs (Pastorekova et al., 2004; Supuran, 2008,
2010a). Whereas α-, β-, and δ-CAs use Zn(II) ions at the active
site, the γ-CAs are probably Fe(II) enzymes (but they are active
also with bound Zn(II) or Co(II) ions), whereas the ζ-class uses
Cd(II) or Zn(II) to perform the physiologic reaction catalysis
(Supuran, 2008, 2010a,b). The 3D fold of the ﬁve enzyme classes
are very different from each other (a nice example of conver-
gent evolution – Supuran, 2010b), as it is their oligomerization
state: α-CAs are normally monomers and rarely dimmers; β-CAs
are dimers, tetramers, or octamers; γ-CAs are trimers, whereas
the δ- and ζ-CAs are probably monomers but in the case of the
last family, three slightly different active sites are present on the
same protein backbone which is in fact a pseudotrimer (Supu-
ran, 2008, 2010a). Many representatives of all these enzyme classes
have been crystallized and characterized in detail, except the δ-
CAs (Supuran, 2008, 2010a,b). The mammalian CAs and their
inhibition/activation have been recently reviewed (Supuran, 2008,
2010a,b) andnodetailed discussionof these enzymes are presented
in this review.
The α-CAs are present in vertebrates, protozoa, algae, and
cytoplasm of green plants and in some Bacteria; the β-CAs are
predominantly found in Bacteria, algae, and chloroplasts of both
mono- as well as dicotyledons, but also in many fungi and some
Archaea (Smith et al., 1999). In bacteria and fungi they are homod-
imers, as shown inFigure 1 for oneof the enzymes from Salmonella
enterica, stCA 1 (Brunzelle et al., submitted;Vullo et al., 2011). The
γ-CAs were found in Archaea and some Bacteria, whereas the δ-
and ζ-CAs seem to be present only in marine diatoms (Smith
et al., 1999; Supuran, 2008, 2010a,b). In most organisms these
enzymes are involved in crucial physiological processes connected
with respiration and transport of CO2/bicarbonate, pH and CO2
homeostasis, electrolyte secretion in a variety of tissues/organs,
biosynthetic reactions (such as gluconeogenesis, lipogenesis, and
ureagenesis), bone resorption, calciﬁcation, tumorigenicity, and
many other physiologic or pathologic processes (thoroughly stud-
ied in vertebrates), whereas in algae, plants and some bacteria they
play an important role in photosynthesis and biosynthetic reac-
tions. In diatoms δ- and ζ-CAs play a crucial role in carbon dioxide
ﬁxation (Smith et al., 1999; Zimmerman et al., 2007; Supuran,
2008, 2010a,b).
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FIGURE 1 |View of the dimeric stCA 1 as obtained by X-ray
crystallography (PDB file 3QY1).The polypeptide chains are represented
as ribbons. The Zn(II) ions (gray spheres) and their ligands (Cys42, Asp44,
His98, and Cys101) are shown as stick representation. The two active sites
are identical and consist of a long channel at the bottom of which is found
the Zn(II) ion in a tetrahedral geometry.
The classical CA inhibitors (CAIs) are the primary sulfon-
amides, RSO2NH2,which are in clinical use for more than 50 years
as diuretics and systemically acting antiglaucoma drugs (Supuran
et al., 2003; Supuran, 2008, 2010a,b). In fact there are around 30
clinically used drugs (or agents in clinical development) belonging
to the sulfonamide or sulfamate class, which show signiﬁcant CAI
inhibitory activity (Supuran, 2008). However, it has emerged in
the last years that sulfonamide/sulfamate CAIs have potential as
anticonvulsant, antiobesity, anticancer, antipain, and antiinfective
drugs (Supuran et al., 2003; Supuran, 2008, 2010a,b). All these
drugs target in fact mammalian CAs, of which 16 different iso-
forms are known so far (Supuran et al., 2003; Supuran, 2008,
2010a,b).
Except vertebrates in which they have been extensively stud-
ied for decades as shown above, CAs are present in many human
pathogens such as themalaria provokingprotozoaPlasmodium fal-
ciparum (Krungkrai and Supuran, 2008; Krungkrai et al., 2008),
bacteria such as Escherichia coli (Cronk et al., 2001), H. pylori
(Nishimori et al., 2006, 2007, 2008),M. tuberculosis (Suarez Covar-
rubias et al., 2005, 2006; Carta et al., 2009; Güzel et al., 2009;
Minakuchi et al., 2009; Nishimori et al., 2009, 2010; Davis et al.,
2011), Brucella spp. (Joseph et al., 2010, 2011; Vullo et al., 2010;
Winum et al., 2010), S. pneumoniae (Burghout et al., 2011), S.
enterica (Vullo et al., 2011), and Haemophilus inﬂuenzae (Cronk
et al., 2006; Hoffmann et al., 2011) as well as pathogenic fungi
(Schlicker et al., 2009). Inhibition of these enzymes started to
be investigated with sulfonamide/sulfamate inhibitors, but several
other chemotypes were also explored, such as phenols, boronic
acids, metal complexing anions, and other similar small mole-
cules. As bacteria predominantly encode for β-class CAs, which
are not present in vertebrates (Smith et al., 1999; Supuran, 2008),
these enzymes started to be considered as possible drug targets for
obtaining antibacterials devoid of the resistance problems men-
tioned above,which affect most classes of antibiotics in clinical use
(Nishimori et al., 2010; Supuran, 2010a,b; Winum et al., 2010).
Here we review the current state-of-the art regarding the bac-
terial CAs cloned and characterized so far, as well as the in vitro
and in vivo inhibition studies of these enzymes, which may reply
to this stringent question: are the bacterial CAs future drug targets
for obtaining conceptually novel antibiotics?
BACTERIAL α-CARBONIC ANHYDRASES AND THEIR
INHIBITION
Table 1 shows the α-CAs cloned and characterized so far from
pathogenic bacteria. The ﬁrst one is an enzyme from Neisseria
gonorrhoeae (Chiricaˇ et al., 1997; Elleby et al., 2001), although
older report mention a similar CA in N. sicca and related species
(which have not been cloned so far; Sanders, 1967; Adler et al.,
1972). The N. gonorrhoeae CA contains 252 amino acid residues
and has a molecular mass of 28 kDa, being quite homologous to
mammalian CAs (Chiricaˇ et al., 1997). A comparison with the
amino acid sequences of human isoforms hCA I and II suggested
that the secondary structures are essentially identical in the bacte-
rial enzyme but several loops are much shorter than in the human
isoforms (Chiricaˇ et al., 1997). This has been conﬁrmed thereafter
by resolving the X-ray crystal structure of this enzyme (Elleby
et al., 2001). Most of the active-site residues are indeed identical
to those found in hCA II, the crucial Zn(II) ion being coordinated
by three His residues and a water molecule/hydroxide ion, being
placed at a bottom of a rather deep and large active site. The bac-
terial enzyme showed a high CO2 hydrase activity, with a kcat of
1.1× 106 s−1 and Km of 20 mM (at pH 9 and 25˚C; Chiricaˇ et al.,
1997). The enzyme also showed esterase activity for the hydroly-
sis of 4-nitrophenyl acetate, similarly to the mammalian isoforms
hCA I and II.
Several studies showed in fact much earlier that the activity
and the growth of N. sicca and related species (N. meningitides,
N. gonorrhoeae, and N. lactamica among others) were inhibited by
the sulfonamide CAIs used clinically acetazolamide and ethoxzo-
lamide (MacLeod and DeVoe, 1981;Vaneechoutte et al., 1988; Naﬁ
et al., 1990). Such inhibitionwas completely overcome by the addi-
tionof exogenous bicarbonate,proving that the processwas indeed
mediated by the bacterial CA. Naﬁ et al. (1990) also observed that
a number of bacterial strains including members of the genera
Pseudomonas, Staphylococcus, Streptococcus, Serratia, and Proteus
also strongly expressed gene products immunologically related to
the N. sicca CA, but these enzymes were not characterized at that
time (and except the S. pneumoniae one, see later in the text, even
today.
But the best studied bacterial α-CA is the one from the gastric
pathogen provoking ulcer and gastric cancer, H. pylori, hpαCA
(Chiricaˇ et al., 2002; Marcus et al., 2005; Shahidzadeh et al., 2005;
Nishimori et al., 2006, 2007) – see Table 1. The genome project of
H. pylori identiﬁed in fact two different classes of CAs, with dif-
ferent subcellular localization: a periplasmic α-class CA (hpαCA)
and a cytoplasmic β-class CA (hpβCA; Nishimori et al., 2008).
These two CAs were shown to be catalytically efﬁcient with almost
identical activity to that of the human isoform hCA I, for the
CO2 hydration reaction, and highly inhibited by many sulfon-
amides/sulfamates, including acetazolamide, ethoxzolamide, top-
iramate, and sulpiride, all clinically used drugs (Nishimori et al.,
2008). Furthermore, certain CAIs, such as acetazolamide and met-
hazolamide, were shown to inhibit the bacterial growth in cell
cultures (Nishimori et al., 2008). Since the efﬁcacy of H. pylori
eradication therapies currently employed has been decreasing due
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Table 1 | CAs from pathogenic bacteria cloned and characterized so far, and their inhibition studies.
Bacterium Family Name Inhibition study Reference
In vitro In vivo
Neisseria gonorrhoeae α – Sulfonamides, anions Sulfonamides Chiricaˇ et al. (1997), Elleby et al. (2001)
Neisseria sicca α – Sulfonamides Sulfonamides Adler et al. (1972), Sanders (1967)
Helicobacter pylori α hpαCA Sulfonamides, anions Sulfonamides Chiricaˇ et al. (2002), Nishimori et al. (2006, 2007),
Marcus et al. (2005), Shahidzadeh et al. (2005)
H. Pylori β hpβCA Sulfonamides, anions Sulfonamides Chiricaˇ et al. (2002), Nishimori et al. (2006, 2007)
Escherichia coli β – NI NI Cronk et al. (2006)
Haemophilus inﬂuenzae β HICA Bicarbonate NI Cronk et al. (2006), Hoffmann et al. (2011)
Mycobacterium tuberculosis β mtCA 1 Sulfonamides NA Suarez Covarrubias et al. (2005, 2006)
β mtCA 2 Sulfonamides NA Minakuchi et al. (2009), Nishimori et al., 2009, 2010
β mtCA 3 Sulfonamides NA Güzel et al. (2009), Carta et al. (2009), Davis et al. (2011),
Winum et al. (2010)
Brucella suis β bsCA 1 Sulfonamides Sulfonamides Joseph et al. (2010), Vullo et al. (2010)
β bsCA 2 Sulfonamides Sulfonamides Joseph et al. (2011), Winum et al. (2010)
Streptococcus pneumoniae β PCA Sulfonamides, anions NI Burghout et al. (2010, 2011)
Salmonella enterica β stCA 1 Sulfonamides, anions NI Vullo et al. (2011)
β stCA 2 Sulfonamides, anions NI Vullo et al. (2011)
Vibrio cholerae Unknown – Sulfonamide Sulfonamide Kovacikova et al. (2010), Abuaita and Withey (2009)
– Means not named; NA, no activity in vivo (presumably due to penetration problems); NI, not investigated.
to drug resistance and side effects of the commonly used drugs, the
dual inhibition of α- and/or β-CAs of H. pylori could be applied
as an alternative therapy in patients with H. pylori infection or for
the prevention of gastroduodenal diseases provoked by this wide-
spread pathogen (Nishimori et al., 2008). In fact, in a pilot study
Shahidzadeh et al. (2005) showed the efﬁcacy of acetazolamide in
the treatment of gastric ulcer. This compound (as well as ethox-
zolamide) were in fact widely used as antiulcer agents in the 70-
and 80-s, although their mechanism of action was not properly
understood at that time (Puscas, 1984).
BACTERIAL β-CARBONIC ANHYDRASES AND THEIR
INHIBITION
As mentioned above, the β-CA class is the most widespread in
bacteria (Smith et al., 1999; Supuran, 2008, 2010a,b). The proof-
of-concept study that such an enzyme may be a drug target has
been published recently by Nishimori et al. (2007) who cloned
and puriﬁed the H. pylori enzyme (hpβCA), showing that it is
highly susceptible to be inhibited by sulfonamides and sulfamates
(see Discussion above for the in vivo data). Afterward, a rather
large number of other β-CAs were cloned, puriﬁed, and character-
ized from other pathogens (Table 1). The X-ray crystal structures
are also available for the E. coli (Cronk et al., 2001), H. inﬂuen-
zae (Cronk et al., 2006), two of the three M. tuberculosis enzymes
(SuarezCovarrubias et al., 2005,2006), andone S. enterica (stCA1)
β-CA (Brunzelle et al., submitted). The 3D folds of these enzymes
are rather conserved and similar to the stCA 1 shown in Figure 1.
The two active sites are identical, being rather long channels at
the bottom of which is found the catalytic zinc ion, tetrahedrally
coordinated by Cys42, Asp44, His98, and Cys101 (in stCA 1). This
is the so called “closed active site,” since these enzymes are not
catalytically active (at pH values< 8.3; Suarez Covarrubias et al.,
2005, 2006). However, at pH values> 8.3, the “closed active site”
is converted to the “open active site” (with gain of catalytic activ-
ity), this being associated with a movement of the Asp residue
from the catalytic Zn(II) ion, with the concomitant coordination
of an incoming water molecule approaching the metal ion. This
water molecule (as hydroxide ion) is in fact responsible for the
catalytic activity, as for the α-CAs investigated in much greater
detail (Suarez Covarrubias et al., 2005, 2006). It should be also
mentioned that some β-CAs possess and open active site at all pH
values (Schlicker et al., 2009).
Many of these enzymes displayed excellent activity for the phys-
iologic CO2 hydration reaction and were inhibited (sometimes
in the low nanomolar range) by sulfonamides and sulfamates
(Nishimori et al., 2010; Supuran, 2010a,b; Winum et al., 2010).
However, in vivo, it has been possible to observe inhibition of
the bacterial growth only for H. pylori, S. penumoniae, and B.
suis (Nishimori et al., 2008; Burghout et al., 2010; Winum et al.,
2010). Especially in the case of M. tuberculosis, although nanomo-
lar and sub-nanomolar in vitro inhibitors were detected (Güzel
et al., 2009), no in vivo inhibition of growth has been observed,
probably because the highly polar sulfonamides have difﬁculties
to penetrate through the bacterial wall of these pathogens (Nishi-
mori et al., 2010). Thus,much work is warranted in order to detect
potent in vitro CAIs that alsowork in vivo, in order to validate these
β-CAs as drug targets.
Table 2 shows the in vitro inhibition data of several of these
enzymes with sulfonamide/sulfamates, which represent one of the
main classes of CAIs (Supuran, 2008, 2010b). Such compounds
are clinically used drugs, e.g.,AAZ, acetazolamide;MZA,methazo-
lamide; EZA, ethoxzolamide; DCP, dichorophenamide; DZA, dor-
zolamide; BRZ, brinzolamide; BZA, benzolamide; TPM, topira-
mate; ZNS, zonisamide; SLP, sulpiride; IND, indisulam; CLX, cele-
coxib; VLX, valdecoxib; as diuretics, antiepileptics, antiglaucoma,
and antiinﬂammatory agents (Supuran, 2008, 2010b). It may be
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Table 2 | In vitro inhibition data of bacterial CAs with sulfonamides and sulfamates, some of which are clinically used drugs (only the enzymes
for which these data were reported in the literature are included).
Compound Ki (μM)
hpαCA hpβCA mtCA 1 mtCA 2 mtCA 3 bsCA 1 bsCA 2 stCA1 stCA2
AAZ 0.021 0.040 0.481 0.009 0.104 0.063 0.303 0.059 0.084
MZA 0.225 0.176 0.781 0.660 0.562 0.054 0.642 0.134 0.068
EZA 0.193 0.033 1.03 0.027 0.594 0.017 0.420 0.528 0.721
DCP 0.378 0.105 0.872 2.01 0.611 0.058 0.112 0.090 0.095
DZA 4.36 0.073 0.744 0.099 0.137 0.021 0.923 0.445 0.607
BRZ 0.210 0.128 0.839 0.127 0.201 0.026 0.625 0.687 0.412
BZA 0.315 0.054 0.810 0.467 0.338 0.075 0.117 0.085 0.098
TPM 0.172 0.032 0.612 0.474 3.02 0.057 0.099 0.624 0.697
ZNS 0.231 0.254 28.68 0.876 0.208 1.85 0.406 5.43 5.70
SLP 0.204 0.035 2.30 0.266 7.92 0.019 0.084 5.64 8.73
IND 0.413 0.143 0.097 0.717 7.84 0.050 0.130 8.86 6.90
CLX nt nt 10.35 0.713 7.76 0.018 0.128 5.83 6.11
VLX nt nt 12.97 0.682 7.81 0.019 0.612 6.85 6.58
Nt, not tested.
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observed that most CAs from bacterial pathogenic organisms are
inhibited in the micro – nanomolar range by many such sulfon-
amide/sulfamate drugs. It should be mentioned that no rational
drug design campaigns have been done to detect better CAIs tar-
geting bacterial CAs so far, but the preliminary screening results
summarized in Table 2 are indeed promising, since a lot of effec-
tive led compounds have been detected. It is envisageable that
more research in this area may lead to highly effective and bacter-
ial CA selective compounds which may validate these enzymes as
antibacterial drug targets.
As mentioned above, it is very probable that many β-CAs (or
enzymes belonging to other CA families) are present in other
bacterial pathogens. For example, in Vibrio cholerae it has been
recently shown that sodium bicarbonate induces cholera toxin
(CT) expression (Abuaita andWithey,2009).Although themecha-
nism for bicarbonate-mediatedCT induction has not been deﬁned
in detail, it has been demonstrated that bicarbonate stimulates
virulence gene expression by enhancing ToxT (a regulatory pro-
tein that directly activates transcription of the genes encoding
CT) activity (Abuaita and Withey, 2009). The sulfonamide CAI
ethoxzolamide, inhibited bicarbonate-mediated virulence induc-
tion, suggesting that conversion of CO2 into bicarbonate by a CA
plays a role in virulence induction in V. cholerae. Thus, bicarbon-
ate was the ﬁrst positive effector for ToxT activity to be identiﬁed.
Given that bicarbonate is present at high concentration in the
upper small intestine where V. cholerae colonizes, bicarbonate
is likely an important chemical stimulus that V. cholerae senses
and that induces virulence during the natural course of infection
(Abuaita and Withey, 2009; Kovacikova et al., 2010). However,
the CA involved in these processes was not yet cloned and char-
acterized, and as a consequence, their inhibition not properly
understood.
CONCLUSION
By catalyzing the simple but highly important hydration of carbon
dioxide to bicarbonate and protons, bacterial CAs are probably
involved in critical steps of the bacterial life cycle, some of which
are important for survival, invasion, and pathogenicity. Bacte-
ria encode such enzymes belonging to the α-, β-, and/or γ-CA
families, but up to now only the ﬁrst two classes have been inves-
tigated in some detail in different species. Indeed, the α-CAs from
Neisseria spp. and H. pylori as well as the β-class enzymes from
E. coli, H. pylori, M. tuberculosis, Brucella spp., S. pneumoniae,
S. enterica, and H. inﬂuenzae have been cloned and character-
ized. For some of these enzymes the X-ray crystal structures
were determined at rather high resolution, allowing for a good
understanding of the catalytic/inhibition mechanisms. However
no adducts with inhibitors of these enzymes have been charac-
terized so far, although in vitro and in vivo inhibition studies
with various classes of inhibitors, such as anions, sulfonamides,
and sulfamates have been reported. Efﬁcient in vitro inhibitors
have been reported for many such enzymes, but only for Neis-
seria spp., H. pylori, B. suis, and S. pneumoniae CAs it has been
possible to evidence inhibition of bacterial growth in vivo. Thus,
bacterial CAs represent at this moment very promising targets
for obtaining antibacterials devoid of the resistance problems of
the clinically used such agents but further studies are needed to
validate these and other less investigated enzymes as novel drug
targets.
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